Products
Benmelstobart Biosimilar Monoclonal Antibody (PD-L1) for Research
Cat No.: GMP-Bios-INN-1099
Anti-PDL1/CD274 therapeutic antibody (Pre-made Benmelstobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Benmelstobart (development code TQ-B2450) is a humanized monoclonal antibody targeting PD-L1 (CD274). It is developed by Chia Tai Tianqing Pharmaceutical Group for cancer and has received regulatory approval.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1099-1mg | 1mg | 3090 |
| GMP-Bios-INN-1099-10mg | 10mg | |
| GMP-Bios-INN-1099-100mg | 100mg | |
| GMP-Bios-INN-1099-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Benmelstobart biosimilar, Whole mAb, Anti-PDL1/CD274 Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody |
| INN Name | Benmelstobart |
| Target | PDL1/CD274 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Crown Bioscience;Apollomics;Chia Tai Tianqing Pharmaceutical Group;Chinese Academy of Medical Sciences;Fudan University;Shandong Cancer Hospital and Institute;Shanghai Tenth Peoples Hospital;The First Affiliated Hospital of Zhengzhou University;Zhengda Tianqing Pharmaceutical Group Co. Ltd. |
| Conditions Approved | Small cell lung cancer |
| Conditions Active | Biliary cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Renal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gynaecological cancer;Hepatitis B;Hodgkin's disease;Liver cancer;Nasopharyngeal cancer;Squamous cell cancer;Acral lentiginous melanoma;Cholangiocarcinoma;Solid tumours |
| Conditions Discontinued | Triple negative breast cancer |
| Production | na |
| Development Tech | na |
